Stephanie Vine

From enhancing drug discovery with AI, to innovations in hot-melt extrusion, continuous processing, generics, and more – check out our free eBook.

In this interview, Claus Zieler shares his thoughts on innovation, EFPIA, emerging markets, and Astellas’s growth in the pharma industry

Is Europe losing its competitiveness in pharma? Claus Zieler of Astellas explains how fragmented reimbursement systems and lengthy approval times are hindering access to medicine.

We get more details on the ready-to-use technologies alliance forged between Schott Pharma, Gerresheimer, and Stevanato.

Looking for words of wisdom and tips on being a leader and advancing your career in the pharmaceutical industry? This is the article list for you.

Here’s a look at recent violations cited in FDA Warning Letters to pharmaceutical companies: fly pupae, cross contamination, trial dosing errors, and more.

We asked over 100 industry professionals for their views on the future of the pharma and biopharma industries, including key disruptors and what can be improved… The key trends? AI, cell and gene therapies, and a need to reduce costs and improve patient access.

Civica Rx is approaching generic drug manufacturing using a nonprofit model – and it’s working. We get the story behind their facility in Petersburg, and learn about how groninger and SKAN were involved.

Researchers purchase Novo Nordisk’s weight loss drug Ozempic online and test for authenticity. Yes, it was counterfeit.

Biogen/Eisai’s Lecanemab (Leqembi) is refused marketing authorization by the European Medicines Agency for the treatment of Alzheimer’s disease.